StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3017% below fair value
$26.41−0.22 (-0.83%)

Close on Nov 20, 2026Market cap $1.36BP/E –Yield 0.00%

Immunocore free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Immunocore's free cash flow for the twelve months ending Jun 30, 2026 was -$41.15M, down 244.6% year over year. For fiscal 2025 it was -$15.05M, down 172.1% from the year before. The highest annual figure on record is $20.89M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.05M-172.1%
FY2024Dec 31, 2024$20.89M–
FY2023Dec 31, 2023-$2.49M–
FY2022Dec 31, 2022-$51.41M–
FY2021Dec 31, 2021-$144.49M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$15.14M-40.7%
Q1 FY2026Mar 31, 2026-$15.56M-11454.7%
Q4 FY2025Dec 31, 2025-$35.54M–
Q3 FY2025Sep 30, 2025-$5.20M-125.6%
Q2 FY2025Jun 30, 2025$25.55M+10.4%
Q1 FY2025Mar 31, 2025$137.00K–
Q4 FY2024Dec 31, 2024-$17.54M–
Q3 FY2024Sep 30, 2024$20.30M+105.5%
Q2 FY2024Jun 30, 2024$23.14M–
Q1 FY2024Mar 31, 2024-$5.02M-166.6%
Q4 FY2023Dec 31, 2023-$18.55M–
Q3 FY2023Sep 30, 2023$9.88M–
Q2 FY2023Jun 30, 2023-$1.35M–
Q1 FY2023Mar 31, 2023$7.54M–

More Immunocore figures

See a number that looks wrong?